Sept 26 (Reuters) - Acurx Pharmaceuticals Inc :
* ACURX ANNOUNCES ADDITIONAL IBEZAPOLSTAT PH2B RESULTS IN CDI AS WELL AS ANTHRAX (B. ANTHRACIS) SUSCEPTIBILITY TO ACX-375 ANALOGUES
* ACURX PHARMACEUTICALS INC: NEW ANALYSES EXTEND DATA ON BENEFICIAL EFFECTS OF IBEZAPOLSTAT ON GUT MICROBIOME
* ACURX PHARMACEUTICALS : CONFIRMED IBEZAPOLSTAT'S FAVORABLE PHARMACOKINETICS SHOWING LOW SYSTEMIC EXPOSURE AND HIGH COLONIC CONCENTRATIONS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.